Welcome to DU!
The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards.
Join the community:
Create a free account
Support DU (and get rid of ads!):
Become a Star Member
Latest Breaking News
General Discussion
The DU Lounge
All Forums
Issue Forums
Culture Forums
Alliance Forums
Region Forums
Support Forums
Help & Search
General Discussion
Related: Editorials & Other Articles, Issue Forums, Alliance Forums, Region ForumsOp-Ed: Are the Immunosuppressed Responding to Two Doses?
Our new study on transplant patients suggests it's not yet safe for them to relax restrictionshttps://www.medpagetoday.com/infectiousdisease/covid19vaccine/92439
Back in March, we published in JAMA and reported here in MedPage Today that only 17% of immunosuppressed transplant patients -- in stark contrast to 100% of immunocompetent people -- mounted detectable antibodies to SARS-CoV-2 after the first dose of mRNA vaccine. Our report was among the top five most read articles in JAMA, and generated substantial -- and understandable -- concern among communities of immunosuppressed people. As a transplant surgeon, I was frustrated and frightened for my patients, and my Johns Hopkins colleagues and I eagerly awaited the results looking at antibody response after full two-dose vaccination. The moment many transplant patients and physicians have been waiting for has finally arrived, but unfortunately the news is not great. We have now published in JAMA second-dose data from our national study of vaccine immune responses in immunosuppressed solid organ transplant recipients.
Among 658 COVID-19-naïve participants who received the full two-dose series of mRNA vaccines, 46% (compared to 83% after just one dose) still had no detectable antibodies, and even among those with detectable antibodies, the levels were still somewhat low. The situation is worse among those taking anti-metabolites: for this group, 57% had no antibodies after full vaccination, compared to 32% with no antibodies among those not taking anti-metabolites. Unfortunately, this blunted antibody response seems to correlate with diminished protective immunity. We are seeing in our own patients, and hearing from around the country, many cases of transplant patients receiving a full vaccine series, thinking they are immune, believing that the CDC guidelines for vaccinated people apply to them, relaxing the masking and distancing behaviours that have protected them for over a year, and sadly finding themselves hospitalized with a new COVID-19 infection. Some have even died. This is highly problematic.
We need more effort and action to spread the word that vaccination does not necessarily mean immunity in this vulnerable population. So, what should our transplant patients do in light of these findings? First and foremost, they should continue to practice all the protective behaviours they have thus far practiced. While the rest of the world is celebrating the new freedoms that come with vaccination, unfortunately the time is not yet right for transplant patients to do so. Eventually we will understand the immune response to vaccines in our patients enough to relax these restrictions, but right now we only know the impact on antibody response (with very little understanding of memory B cell and T cell response, which are both important), and what we know is not encouraging. Transplant patients should also make sure that everyone around them gets vaccinated, so at least their environments are safer. And, of course, this is yet another reason that everyone should want to get vaccinated -- to protect the vulnerable who cannot achieve immunity for themselves, and ultimately help reach herd immunity.
So, what is next? Will other platforms perform better? If someone had no, or limited, immune response to two doses, will a third dose help? Should the third dose be of the sample platform or a different platform? Is it reasonable for some patients to reduce immunosuppression, risking rejection, just to achieve an immune response? How do B cell and T cell responses look in immunosuppressed people? In the meantime, should people with no vaccine response receive pre-exposure exogenous antibody preparations for interim protection? We continue to strive to answer these questions, and enrolment in our study remains open and ongoing.
snip
InfoView thread info, including edit history
TrashPut this thread in your Trash Can (My DU » Trash Can)
BookmarkAdd this thread to your Bookmarks (My DU » Bookmarks)
2 replies, 721 views
ShareGet links to this post and/or share on social media
AlertAlert this post for a rule violation
PowersThere are no powers you can use on this post
EditCannot edit other people's posts
ReplyReply to this post
EditCannot edit other people's posts
Rec (10)
ReplyReply to this post
2 replies
= new reply since forum marked as read
Highlight:
NoneDon't highlight anything
5 newestHighlight 5 most recent replies
Op-Ed: Are the Immunosuppressed Responding to Two Doses? (Original Post)
Celerity
May 2021
OP
Sympthsical
(9,076 posts)1. And that's why I'll keep my mask on
I'm young and vaccinated. I'll be fine. But I don't know who's around me, who's vulnerable.
It's not only about me. It's about protecting others. Always has been.
Celerity
(43,420 posts)2. List of Antimetabolites
https://www.drugs.com/drug-class/antimetabolites.html?condition_id=0&generic=0&sort=reviews&order=desc
Xeloda
Generic name: capecitabine
Hydrea
Generic name: hydroxyurea
Gemzar
Generic name: gemcitabine
Otrexup
Generic name: methotrexate
Rheumatrex Dose Pack
Generic name: methotrexate
Purinethol
Generic name: mercaptopurine
Leustatin
Generic name: cladribine
Folotyn
Generic name: pralatrexate
Fludara
Generic name: fludarabine
Alimta
Generic name: pemetrexed
Xatmep
Generic name: methotrexate
Trexall
Generic name: methotrexate
Tabloid
Generic name: thioguanine
Siklos
Generic name: hydroxyurea
Rasuvo
Generic name: methotrexate
Pemfexy
Generic name: pemetrexed
Oforta
Generic name: fludarabine
Mylocel
Generic name: hydroxyurea
Mavenclad
Generic name: cladribine
Infugem
Generic name: gemcitabine
FUDR
Generic name: floxuridine
Droxia
Generic name: hydroxyurea
DepoCyt
Generic name: cytarabine liposomal
Dacogen
Generic name: decitabine
Clolar
Generic name: clofarabine
Arranon
Generic name: nelarabine
Adrucil
Generic name: fluorouracil
Xeloda
Generic name: capecitabine
Hydrea
Generic name: hydroxyurea
Gemzar
Generic name: gemcitabine
Otrexup
Generic name: methotrexate
Rheumatrex Dose Pack
Generic name: methotrexate
Purinethol
Generic name: mercaptopurine
Leustatin
Generic name: cladribine
Folotyn
Generic name: pralatrexate
Fludara
Generic name: fludarabine
Alimta
Generic name: pemetrexed
Xatmep
Generic name: methotrexate
Trexall
Generic name: methotrexate
Tabloid
Generic name: thioguanine
Siklos
Generic name: hydroxyurea
Rasuvo
Generic name: methotrexate
Pemfexy
Generic name: pemetrexed
Oforta
Generic name: fludarabine
Mylocel
Generic name: hydroxyurea
Mavenclad
Generic name: cladribine
Infugem
Generic name: gemcitabine
FUDR
Generic name: floxuridine
Droxia
Generic name: hydroxyurea
DepoCyt
Generic name: cytarabine liposomal
Dacogen
Generic name: decitabine
Clolar
Generic name: clofarabine
Arranon
Generic name: nelarabine
Adrucil
Generic name: fluorouracil